Showing 2031-2040 of 2652 results for "".
- SIFI Receives European Commission Approval for Akantiorhttps://modernod.com/news/avanzanite-bioscience-secures-european-commission-approval-for-akantior-first-treatment-for-acanthamoeba-keratitis/2482417/SIFI announced the European Commission has approved Akantior (polihexanide) for the treatment of acanthamoeba keratitis (AK) in adults and children from 12 years of age. Akantior is the first and only approved therapy for people suffering from AK in Europe. AK is an ultr
- Inaugural Eyecelerator Innovation Award Presented to Regeneron Executiveshttps://modernod.com/news/inaugural-eyecelerator-innovation-award-presented-to-regeneron-executives/2482404/Leonard Schleifer, MD, PhD, and George Yancopoulos, MD, PhD, of Regeneron Pharmaceuticals were awarded the first Eyecelerator Innovation Award. "This year's Eyecelerator Innovation Award honors the remarkable physician-led, science-dr
- Orbis Launches AI-Led Diabetic Retinopathy Screening Project in Vietnamhttps://modernod.com/news/orbis-launches-ai-led-diabetic-retinopathy-screening-project-in-vietnam/2482401/Orbis has launched an AI-led diabetic retinopathy (DR) project in Vietnam, aiming to screen 72,000 people with diabetes over the next 3 years. The initiative focuses on providing AI-driven screenings, specialized training for screening teams, and enhancing community awareness of diabeti
- LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Diseasehttps://modernod.com/news/lumithera-announces-first-cpt-code-to-report-photobiomodulation-therapy-in-retinal-disease/2482389/LumiThera announced a new Category III CPT code, effective January 1, 2025. The code, "Photobiomodulation therapy of retina, single session,” was approved by the AMA’s CPT Editorial Panel at the May 2024 meeting.[1] The LIGHTSITE III clinical trial was a
- Richard Rosen, MD, Receives Founders Award From ASRShttps://modernod.com/news/richard-rosen-md-receives-founders-award-from-asrs/2482366/The American Society of Retina Specialists (ASRS) is honoring Richard B. Rosen, MD, ScD (hon), FACS, FASRS, FARVO, CRA, the Belinda Bingham Pierce and Gerald G. Pierce Distinguished Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai, with
- New Data for Susvimo Demonstrates Sustained Efficacy in DME and DRhttps://modernod.com/news/new-data-for-susvimo-demonstrates-sustained-efficacy-in-dme-and-dr/2482365/Genentech and Roche announced 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively. Susvimo, which is being
- Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term DME Studyhttps://modernod.com/news/vabysmo-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-dme-study/2482363/At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden, Genentech announced new, 4-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo (faricimab-svoa) was well tolerated in people with diabetic mac
- Perry J. Sternberg Joins Sydnexis as Chief Executive Officerhttps://modernod.com/news/perry-j-sternberg-joins-sydnexis-as-chief-executive-officer/2482358/Sydnexis has announced the appointment of Perry J. Sternberg as Chief Executive Officer and a member of the Board of Directors. Mr. Sternberg is a pharma/biotech executive with more than 30 years in the industry and 15 years in eye care. Immediately prior to joining Sydnexis,
- Okyo Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101https://modernod.com/news/okyo-pharma-to-initiate-neuropathic-corneal-pain-trial-for-ok-101/2482353/Okyo Pharma announced its plan to advance OK-101 into a phase 2 clinical trial of neuropathic corneal pain which is expected to begin in Q3 2024. This 1-year study is supported by preclinical animal model data and statistically significant pain relief observe
- Hospital in Poland is First Teaching Institution to Use Haag-Streit's Eyesi Indirect Ophthalmoscope ROP Simulatorshttps://modernod.com/news/hospital-in-poland-is-first-teaching-institution-to-use-haag-streits-eyesi-indirect-ophthalmoscope-rop-simulators/2482352/Haag-Streit announced it has enabled trainee ophthalmologists across Poland to become competent in the skills required for effective ROP examination in a lifelike, yet risk-free, environment. The University Clinical Hospital, Poland, will be the first teaching institution globally to use four Eye